Table 7.
Clinicopathologic characteristics in VNPI intermediate scores according to treatment (TM; total mastectomy in intermediate VNPI score)
| Variable | No RTx (n=14) | RTx (n=61) | TM (n=43) | P |
|---|---|---|---|---|
| Age (yr) | 49.1±9.5 | 48.1±7.9 | 48.7±9.5 | .979 |
| ≤40 | 2(14.3%) | 7(11.7%) | 6(14.0%) | |
| 41-60 | 11(78.6%) | 50(82.0%) | 33(76.7%) | |
| ≥61 | 1(7.1%) | 4(6.6%) | 4(9.3%) | |
| Microcalcification | .983 | |||
| Yes | 9(64.3%) | 38(62.3%) | 28(65.1%) | |
| No | 5(35.7%) | 23(37.7%) | 15(34.9%) | |
| Multifocality | .314 | |||
| Yes | 1(7.1%) | 9(14.8%) | 10(23.3%) | |
| No | 13(92.9%) | 52(85.2%) | 33(76.7%) | |
| Tumor size (mm) | 13.93±12.07 | 29.90±18.11 | 50.74±23.49 | .001 |
| ≤15 | 11(78.6%) | 14(23.0%) | 1(2.3%) | |
| 16-40 | 2(14.3%) | 30(49.2%) | 15(34.9%) | |
| ≥41 | 1(7.1%) | 17(27.9%) | 27(62.8%) | |
| Tumor grade | .360 | |||
| 1 | 2(14.3%) | 8(13.1%) | 1(2.3%) | |
| 2 | 7(50.0%) | 36(59.0%) | 28(65.1%) | |
| 3 | 5(35.7%) | 17(27.9%) | 14(32.6%) | |
| Margin (mm) | 8.93±7.97 | 7.80±7.58 | .221 | |
| >9 | 5(35.7%) | 18(29.5%) | - | |
| 1-9 | 9(64.3%) | 32(52.5%) | - | |
| <1 | 0 | 11(18.0%) | - | |
| VNPI score | 7.5±0.7 | 8.2±0.8 | 8.0±0.9 | .021 |
| Receptor status | ||||
| ER positive | 13(92.9%) | 40(65.6%) | 28(65.1%) | .110 |
| PR positive | 10(71.4%) | 38(62.3%) | 21(48.8%) | .240 |
| C-erbB2 | .636 | |||
| 0 | 3(21.4%) | 6(9.8%) | 6(14.0%) | |
| 1+ | 2(14.3%) | 10(16.4%) | 11(25.6%) | |
| 2+ | 3(21.4%) | 18(29.5%) | 6(14.0%) | |
| 3+ | 6(42.9%) | 26(42.6%) | 18(41.9%) | |
| Unknown | 0 | 1(1.7%) | 2(4.7%) | |
| Ki67 status (%) | 12.8±12.39 | 13.65±15.54 | 12.91±15.94 | .847 |
| Tamoxifen | 12(85.7%) | 43(68.9%) | 30(69.8%) | .467 |
| Recurrence | 0 | 5(8.3%) | 0 | .418 |